Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mayo Clin Proc. 2013 Aug;88(8):841-53. doi: 10.1016/j.mayocp.2013.05.001.

My treatment approach to the management of ulcerative colitis.

Author information

  • 1Department of Medicine, New York University School of Medicine, New York, NY; North Shore University Hospital-Long Island Jewish Health System, Manhasset, NY; and St Francis Hospital, Roslyn, NY. Electronic address: Seymourkatz.md@gmail.com.

Abstract

Ulcerative colitis diagnosis and management represent a challenge for clinicians. The disguises of ischemia and acute infectious colitis continue to confound the diagnosis. The therapeutic options have remarkably expanded in the way of immunomodulators, biologics, or ileoanal pouch surgery, yet all carry potential considerable risks. These risks can confuse and impair patient acceptance, particularly elderly patients and men younger than 30 years. Predictors of outcome of medical and surgical therapy have improved but are far from complete. Nevertheless, therapies focused on the specific patient's condition continue to offer hope.

Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

KEYWORDS:

BMS; C-reactive protein; CBC; CMV; CRP; FCP; GETAID; Groupe d'Etude Thérapeutique des Affections Inflammatories du Tube Digestif; IBD; PIANO; Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes; TNF; TPMT; UC; bowel movements; complete blood cell; cytomegalovirus; fecal calprotectin; irritable bowel disease; thiopurine methyltransferase; tumor necrosis factor; ulcerative colitis

PMID:
23910410
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk